Wet AMD

Biosimilar

Diabetic Eye Awareness

Diabetic Macular Edema

Diabetic Retinopathy

Geographic Atrophy

Imaging

Inherited Retinal Diseases

Ophthalmology

Retina Technology

Retinal Surgery

Uveitis

News

All News

Blogs

Media

Case-Based Roundtable Series

Expert Interviews

Eyeviews

Insights

Medical World News

Podcasts

Rapid Readouts

Viewpoints

Conference

Conference Coverage

Conference Listing

Publications

Modern Retina Digital Edition

Supplements And Featured Publications

Resources

Between the Lines

CME/CE

Partners

Subscribe

Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

About

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Modern Retina | Ophthalmology News, Events & Expert Insights

Facebook

LinkedIn

Spotlight

Clinical

1rem

View

Aflibercept 8mg in Neovascular AMD and DMO: Insights from PULSAR and PHOTON Trials

Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD.

Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD

Videos

Dr. Marion Munk reviews clinical trials of high-dose aflibercept in neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO), providing insights and discussing the clinical implications derived from these trials.

Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.

Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.

Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO

clinical

Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD

EP: 1.Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD

EP: 2.Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO